SCHEMBL5056646

SCHEMBL5056646

CCc1ccc2c(c1)C(C)(C)c1cc3c(cc1-2)C(C)(C)c1cc(N)ccc1-3

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 3/20 0.42
CHEK1 O14757 1/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
RET P07949 1/20 0.37
MET P08581 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
LTK P29376 1/20 0.37
PRKX P51817 1/20 0.37
NEK2 P51955 1/20 0.37
JAK3 P52333 1/20 0.37
BTK Q06187 1/20 0.37
MAP4K2 Q12851 1/20 0.37
DYRK1A Q13627 1/20 0.37
TAOK1 Q7L7X3 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
ALDH1A1 P00352 6/20 0.36
NPC1 O15118 6/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14174227 0.90 PDK2 (0.40) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL14073332 0.85 PDK2 (0.43) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL29479852 0.83 PDK2 (0.44) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL30340812 0.83 PDK2 (0.44) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL349824 0.83 PDK2 (0.44) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL5054456 0.83 PDK2 (0.56) PDK2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL15861383 0.82 SKP2 (0.50) PDK2CHEK1PRKD3MAP4K4RET
SCHEMBL5056100 0.81 PDK2 (0.41) PDK2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5052837 0.80 PDK2 (0.40) PDK2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL18559923 0.79 PDK2 (0.44) PDK2ALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334058-B2 Emitters for systems which emit in dark blue; stable, significantly longer lifetime; can be sublimed well without decomposition; easier to process; more suitable for OLEDs; operating voltage, power efficiency remain unchanged at large layer thicknesses; important for production of full-colour displays MERCK PATENT GMBH (DE) 2012-12-18 US disclosed
US-8334058-B2 Emitters for systems which emit in dark blue; stable, significantly longer lifetime; can be sublimed well without decomposition; easier to process; more suitable for OLEDs; operating voltage, power efficiency remain unchanged at large layer thicknesses; important for production of full-colour displays MERCK PATENT GMBH (DE) 2012-12-18 US disclosed
US-8334058-B2 Emitters for systems which emit in dark blue; stable, significantly longer lifetime; can be sublimed well without decomposition; easier to process; more suitable for OLEDs; operating voltage, power efficiency remain unchanged at large layer thicknesses; important for production of full-colour displays MERCK PATENT GMBH (DE) 2012-12-18 US disclosed
US-20080145708-A1 Compounds For Organic Electronic Devices MERCK PATENT GMBH (DE) 2008-06-19 US disclosed
US-20080145708-A1 Compounds For Organic Electronic Devices MERCK PATENT GMBH (DE) 2008-06-19 US disclosed
US-20080145708-A1 Compounds For Organic Electronic Devices MERCK PATENT GMBH (DE) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080145708-A1 Compounds For Organic Electronic Devices TYR, TOE1, GPX1 PDK2 1138/4885CHEK1 3928/4885PRKD3 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.